AMAG has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AMAG has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
AMAG Pharmaceuticals's average Accounts Receivable for the three months ended in Sep. 2020 was $66.4 Mil. AMAG Pharmaceuticals's Revenue for the three months ended in Sep. 2020 was $93.1 Mil. Hence, AMAG Pharmaceuticals's Days Sales Outstanding for the three months ended in Sep. 2020 was 65.03.
The historical rank and industry rank for AMAG Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:
AMAG Pharmaceuticals's Days Sales Outstanding declined from Sep. 2019 (87.52) to Sep. 2020 (65.03).
The historical data trend for AMAG Pharmaceuticals's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMAG Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | |||||||||||
Days Sales Outstanding | Get a 7-Day Free Trial | 56.20 | 75.32 | 67.92 | 64.49 | 94.74 |
AMAG Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | |
Days Sales Outstanding | Get a 7-Day Free Trial | 87.52 | 87.57 | 133.33 | 148.40 | 65.03 |
For the Biotechnology subindustry, AMAG Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, AMAG Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where AMAG Pharmaceuticals's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
AMAG Pharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Dec. 2019 is calculated as
Days Sales Outstanding (A: Dec. 2019 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Dec. 2018 ) | + | Accounts Receivable (A: Dec. 2019 )) | / | count ) | / | Revenue (A: Dec. 2019 ) | * | Days in Period |
= | ( (75.347 | + | 94.163) | / | 2 ) | / | 326.546 | * | 365 |
= | 84.755 | / | 326.546 | * | 365 | ||||
= | 94.74 |
AMAG Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Sep. 2020 is calculated as:
Days Sales Outstanding (Q: Sep. 2020 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Jun. 2020 ) | + | Accounts Receivable (A: Sep. 2020 )) | / | count ) | / | Revenue (A: Sep. 2020 ) | * | Days in Period |
= | ( (65.104 | + | 67.608) | / | 2 ) | / | 93.106 | * | 365 / 4 |
= | 66.356 | / | 93.106 | * | 365 / 4 | ||||
= | 65.03 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMAG Pharmaceuticals (NAS:AMAG) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Thank you for viewing the detailed overview of AMAG Pharmaceuticals's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Camber Capital Management Lp | 10 percent owner | 101 HUNTINGTON AVENUE, SUITE 2101, BOSTON MA 02199 |
Anthony Casciano | officer: Chief Operating Officer | C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451 |
Brian Piekos | officer: Interim CFO | C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
David Edward Johnson | director, 10 percent owner | 590 MADISON AVENUE, NEW YORK NY 10022 |
James R Sulat | director | |
Davey Scoon | director | C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
John A. Fallon | director | C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730 |
Anne M. Phillips | director | C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406 |
Paul R. Fonteyne | director | C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116 |
Gino Santini | director | C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
Scott Dunseth Myers | director, officer: President & CEO | C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121 |
Kelly Schick | officer: Chief Human Resources Officer | C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
Armistice Capital, Llc | 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Armistice Capital Master Fund Ltd. | 10 percent owner | C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Steven Boyd | 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By PRNewswire PRNewswire • 10-15-2020
By Marketwired Marketwired • 10-15-2020
By Marketwired Marketwired • 10-02-2020
By Marketwired Marketwired • 10-07-2020
By PRNewswire PRNewswire • 11-06-2020
By Marketwired Marketwired • 10-06-2020
By Marketwired Marketwired • 09-09-2020
By PRNewswire PRNewswire • 10-03-2020
By PRNewswire PRNewswire • 11-16-2020
By PRNewswire PRNewswire • 10-30-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.